Useful, accessible, and predictive biomarkers for discriminating between ovarian cancer and benign adnexal masses are provided. Specifically, peptide biomarkers present in bodily fluid samples such as cervical-vaginal fluid (CVF) have been identified as having particularly robust diagnostic for identifying whether ovarian masses such as adnexal masses are benign, and ruling our ovarian cancer. The biomarker peptides disclosed herein therefore provide significantly enhanced sensitivity and specificity levels relative to extant methods for distinguishing benign ovarian masses from ovarian cancers. The biomarkers provide a timely and cost-efficient diagnostic capable of being used in a selection process to identify patients for whom treatment, which may include surgical resection and/or monitoring, may be performed by an obstetric gynecologist rather than a gynecologic oncologist.

The present invention relates generally to methods and materials pertaining to assays, for example immunoassays, for biomarkers in body fluids e.g. blood. The invention also relates to diagnostic or screening methods for infections, and methods of differentiating between infectious and non-infectious conditions in mammals, particularly equines, for monitoring response to anti-infective/antibiotic therapy. The invention further relates to a test fluid collection system adapted to permit dilution and analysis of the collected test fluid. The invention further relates to monitoring exertional rhabdomyolysis in equines, and assay devices for all these things.

A method carried out by a system configured to analyze platelet aggregation includes retaining a ferromagnetic object at an elevation of a chamber in which a sample of blood or plasma is disposed. The ferromagnetic object is retained at the elevation for a period of time. The ferromagnetic object is then released from the elevation. The ferromagnetic object minimal position is measured following the release of the ferromagnetic object. The object minimal position may be correlated with amount of platelet aggregation in the sample.

A biomarker panel including a four-panel test for clotting that detects soluble fibrin (SF), thrombin-antithrombin complex (TAT), antithrombin III (ATIII), and plasminogen activator inhibitor (PAI-1). A biomarker panel including a three-panel test for glycocalyx integrity that detects syndecan-1 (SDC1), heparan sulfate (HS), and hyaluronidase (HAD). A biomarker panel including a test that detects a biomarker chosen from soluble fibrin (SF), thrombin-antithrombin complex (TAT), antithrombin III (ATIII), plasminogen activator inhibitor (PAI-1), syndecan-1 (SDC1), heparan sulfate (HS), hyaluronidase (HAD), and combinations thereof. A kit including a biomarker panel, instructions for use, materials to take and apply samples to the panel, and descriptions of biomarker levels and their meaning. Methods of detecting the presence of vascular disease, determining the stage of vascular disease, monitoring the progress of vascular disease treatments, and monitoring the efficacy of drugs during drug development.

This disclosure describes portable bio-nano-chip assays, methods and compositions for diagnosing and assessing pathogen-mediated diseases or infections at point-of-care using biological samples. The assays, methods and compositions provide in a more convenient, less expensive, and less time-consuming sampling and analysis.

The present invention relates generally to methods and materials pertaining to assays, for example immunoassays, for biomarkers in body fluids e.g. blood. The invention also relates to diagnostic or screening methods for infections, and methods of differentiating between infectious and non-infectious conditions in mammals, particularly equines, for monitoring response to anti-infective/antibiotic therapy. The invention further relates to a test fluid collection system adapted to permit dilution and analysis of the collected test fluid. The invention further relates to monitoring exertional rhabdomyolysis in equines, and assay devices for all these things.

The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.

Compositions and methods for measuring coagulation parameters using very small volumes of blood are provided. Advantageously, the methods described herein can be performed from a single drop of blood (about 20 μL) while generally leaving enough sample to perform other measurements, optionally in a multiplexed format. The methods and devices do not require a skilled operator and can be performed at the point of service, which can be an important feature for managing blood coagulation disorders and treatments thereof.

Provided is a biomaterial detection sensor. The biomaterial detection sensor comprises a substrate and a detection probe including a metal nanoparticle deposited on the substrate, and an erythrocyte membrane conformally covering the metal nanoparticle, wherein the detection probe may selectively react with fibrinogen.

The present invention discloses crystal structure of Staphylococcus aureus Clumping factor A (ClfA) in complex with fibrinogen (Fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of ClfA targeted vaccines and therapeutic agents (including monoclonal antibodies). In addition, the present invention discloses isolated and purified engineered Staphylococcus clumping factor A protein (ClfA) with a stabilized, closed conformation and immunogenic compositions thereof including methods of treating a Staphylococcus infection in an individual.